Most Employers Are Not Expanding GLP-1 Coverage — and Some Are Cutting It
Despite growing demand, only about 36% of employers cover GLP-1 drugs for weight loss — a figure that has barely budged from last year.
CONTINUE READING ▸
Opinion: Taking Ozempic Without Being Overweight Raises Cultural Concerns
A New York Times opinion piece uses writer Caroline Calloway's personal essay about taking Ozempic — despite not being overweight — as a jumping-off point to examine how GLP-1 drugs are being used beyond their intended medical purpose.
CONTINUE READING ▸
1 in 9 Americans Is Now Taking a GLP-1 Weight Loss Drug
According to a new Gallup poll, 11% of Americans are currently on a GLP-1 medication like Wegovy, with 15% having tried one at some point — a sharp rise from 6% just a year ago. The numbers highlight how quickly these drugs have gone from niche treatments to mainstream weight loss tools.
CONTINUE READING ▸
GLP-1 Drug Use Has Nearly Doubled in Two Years, Gallup Finds
A new Gallup survey confirms that GLP-1 weight loss drug use has surged to record levels in the U.S., with 11% of Americans currently taking one of these medications. This represents a massive jump over the past two years and reflects growing mainstream acceptance of drugs like Ozempic and Wegovy.
CONTINUE READING ▸
Yale Study Finds Online GLP-1 Prescriptions Dangerously Easy to Obtain
A secret shopper study by Yale University researchers, published in JAMA, found that telehealth platforms are prescribing GLP-1 weight loss drugs with little medical oversight — confirming long-standing concerns from doctors.
CONTINUE READING ▸
Record 15% of Americans Have Now Tried GLP-1 Weight Loss Drugs
A new Gallup poll shows GLP-1 drug use has surged dramatically, with 15% of U.S. adults having tried medications like Ozempic or Wegovy — up from just 6% in 2024. Currently, 11% of adults are actively taking one of these drugs. The trend coincides with declining obesity rates across the country.
CONTINUE READING ▸
New Research Looks at Whether GLP-1 Drugs Are Worth Their High Price
Researchers are trying to quantify the long-term health benefits of GLP-1 drugs — like reduced risk of heart disease and diabetes — to determine if their steep cost is justified.
CONTINUE READING ▸
A Natural Fiber That Boosts GLP-1 Hormones Could Soon Be Added to Foods
European food safety regulators have approved a specific type of dietary fiber that naturally triggers the body to release GLP-1, the same hunger-reducing hormone that Ozempic mimics.
CONTINUE READING ▸
Medicare Will Start Covering GLP-1 Weight Loss Drugs Starting July 1
Starting July 1, Medicare will cover GLP-1 obesity drugs like Wegovy, opening up access for millions of seniors who previously couldn't afford them.
CONTINUE READING ▸
GLP-1 Drugs Could Soon Be Taken Just Once Every Three Months
Researchers are working on new formulations of GLP-1 drugs that could reduce how often patients need to take them — potentially shifting from weekly injections to just once a quarter.
CONTINUE READING ▸
Some GLP-1 Users Feel Fat Even After Losing Weight — Here’s Why
A psychological phenomenon called "ghost fat" is being reported among people who've lost significant weight on GLP-1 drugs — they continue to see themselves as overweight even after the pounds are gone, similar to body dysmorphia.
CONTINUE READING ▸
Breast Cancer Patients on GLP-1 Drugs Had Higher Survival Rates
A large observational study found that breast cancer patients who took GLP-1 drugs had better survival outcomes compared to those who didn't. Researchers say the findings are promising but call for formal clinical trials to confirm whether the drugs are actually responsible for the benefit.
CONTINUE READING ▸
Why GLP-1 Drugs Can Be Risky for People with Disordered Eating
A therapist who specializes in eating disorders addresses the complicated pull that GLP-1 weight-loss drugs can have for people already struggling with their relationship with food.
CONTINUE READING ▸
A DNA Test Claims to Predict Whether GLP-1 Drugs Will Work for You
A new at-home genetic test called MyPhenome claims it can tell you whether your body is likely to respond to GLP-1 weight-loss drugs before you spend thousands of dollars on them.
CONTINUE READING ▸
GLP-1 Users Are Walking Less and Exercising Less, Study Finds
A new study found that people taking GLP-1 weight-loss drugs became less physically active over time — daily steps dropped from about 5,047 to 4,487, and moderate exercise fell from 28 to 22 minutes per day.
CONTINUE READING ▸
Employers Are Rethinking Whether to Keep Covering GLP-1 Weight-Loss Drugs
As GLP-1 drugs like Wegovy become more popular, employers are under growing financial pressure and some are reconsidering whether to cover them for weight loss at all.
CONTINUE READING ▸
Experts Weigh In on Whether You Need GLP-1 Drugs Forever
If you're taking a GLP-1 drug like Ozempic or Wegovy, you might be wondering whether you'll need to stay on it indefinitely. Experts are increasingly discussing the long-term safety and necessity of these medications, since weight often returns when people stop taking them.
CONTINUE READING ▸Online GLP-1 Weight Loss Drug Sales Raise Safety Concerns
Many telehealth companies are making GLP-1 weight loss drugs easily available online as demand soars. This easy access is raising concerns about potential overdoses and safety issues when these powerful medications aren't properly supervised by healthcare providers.
CONTINUE READING ▸
Medicare Will Cover GLP-1 Weight Loss Drugs Starting in 2026
Medicare beneficiaries will be able to get coverage for GLP-1 medications for weight loss starting in 2026. Currently, Medicare covers these drugs for specific conditions like type 2 diabetes, but the expanded coverage will include weight management.
CONTINUE READING ▸
Weight Loss Drugs May Reshape Brain and Nervous System
New research suggests GLP-1 weight loss drugs might be changing how the brain and nervous system function. Scientists are investigating whether these medications could have broader effects on brain structure and neural networks beyond their intended weight loss benefits.
CONTINUE READING ▸